Literature DB >> 12698237

Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy.

Frédéric Debelle1, Joëlle Nortier, Volker M Arlt, Eric De Prez, Anne Vienne, Isabelle Salmon, David H Phillips, Monique Deschodt-Lanckman, Jean-Louis Vanherweghem.   

Abstract

Chinese-herb nephropathy (CHN) is a progressive renal interstitial fibrosis initially reported after concomitant intake of an anorexigen, (dex)fenfluramine, and a Chinese herb ( Aristolochia fangchi) containing nephrotoxic and carcinogenic aristolochic acid (AA). We thus tested the possible enhancing effect of the active enantiomer dexfenfluramine (DXF) on AA nephrotoxicity in a rat model for CHN. Groups of 12 salt-depleted male Wistar rats received daily subcutaneous injections of 7 mg/kg body weight DXF (DXF group), 7 mg/kg body weight AA (AA group), a combination of the same doses of AA and DXF (AA+DXF group), or vehicle (control group) for up to 35 days. Six animals per group were killed on day 10 and the remaining six on day 35. Renal function was evaluated by determining serum creatinine and urinary leucine aminopeptidase activity. Histological evaluation of kidney samples was performed and tubulointerstitial injuries were semiquantified. The DXF group did not differ from controls for any parameter. Similarly elevated serum creatinine levels, decreased leucine aminopeptidase enzymuria, and renal lesions were observed in the AA and the AA+DXF groups after both 10 and 35 days. The formation of specific AA-DNA adducts in liver and renal tissue samples was assessed by the (32)P-postlabelling method. Specific AA-DNA adduct levels were significantly increased in kidney tissues from AA+DXF rats compared with AA rats. These functional and histological data suggest that DXF does not enhance AA nephrotoxicity in a rat model for CHN. Further investigations are needed to clarify the mechanism by which DXF may enhance AA-DNA adduct formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12698237     DOI: 10.1007/s00204-003-0438-y

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  6 in total

1.  A meta-analysis of medicinal plants to assess the evidence for toxicity.

Authors:  Sarah Chen; Amandio Vieira
Journal:  Interdiscip Toxicol       Date:  2010-06

2.  DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver.

Authors:  Nan Mei; Volker M Arlt; David H Phillips; Robert H Heflich; Tao Chen
Journal:  Mutat Res       Date:  2006-09-28       Impact factor: 2.433

3.  Revealing a Pre-neoplastic Renal Tubular Lesion by p-S6 Protein Immunohistochemistry after Rat Exposure to Aristolochic Acid.

Authors:  Alexandra Gruia; Patrycja Gazinska; Diana Herman; Valentin Ordodi; Calin Tatu; Peter Mantle
Journal:  J Kidney Cancer VHL       Date:  2015-09-08

4.  Alisol A 24-Acetate and Alisol B 23-Acetate Induced Autophagy Mediates Apoptosis and Nephrotoxicity in Human Renal Proximal Tubular Cells.

Authors:  Chunfei Wang; Liang Feng; Liang Ma; Haifeng Chen; Xiaobin Tan; Xuefeng Hou; Jie Song; Li Cui; Dan Liu; Juan Chen; Nan Yang; Jing Wang; Ying Liu; Bingjie Zhao; Gang Wang; Yuanli Zhou; Xiaobin Jia
Journal:  Front Pharmacol       Date:  2017-03-31       Impact factor: 5.810

5.  The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro.

Authors:  Mateja Sborchia; Eric G De Prez; Marie-Hélène Antoine; Lucie Bienfait; Radek Indra; Gabriel Valbuena; David H Phillips; Joëlle L Nortier; Marie Stiborová; Hector C Keun; Volker M Arlt
Journal:  Arch Toxicol       Date:  2019-10-10       Impact factor: 5.153

6.  The safety of Homnawakod herbal formula containing Aristolochia tagala Cham. in Wistar rats.

Authors:  Pinpat Tripatara; Winita Onlamul; Suksalin Booranasubkajorn; Jantanee Wattanarangsan; Sukit Huabprasert; Natchagorn Lumlerdkij; Pravit Akarasereenont; Tawee Laohapand
Journal:  BMC Complement Altern Med       Date:  2012-10-03       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.